Susan M. Blaney

15.5k total citations · 1 hit paper
267 papers, 11.4k citations indexed

About

Susan M. Blaney is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, Susan M. Blaney has authored 267 papers receiving a total of 11.4k indexed citations (citations by other indexed papers that have themselves been cited), including 128 papers in Molecular Biology, 121 papers in Oncology and 93 papers in Neurology. Recurrent topics in Susan M. Blaney's work include Neuroblastoma Research and Treatments (86 papers), Glioma Diagnosis and Treatment (66 papers) and Cancer therapeutics and mechanisms (63 papers). Susan M. Blaney is often cited by papers focused on Neuroblastoma Research and Treatments (86 papers), Glioma Diagnosis and Treatment (66 papers) and Cancer therapeutics and mechanisms (63 papers). Susan M. Blaney collaborates with scholars based in United States, Canada and Switzerland. Susan M. Blaney's co-authors include Peter C. Adamson, Mark Krailo, Stacey L. Berg, Frank M. Balis, Brenda J. Weigel, Ashish M. Ingle, Joel M. Reid, Mark L. Bernstein, Stephan D. Voss and Charlotte H. Ahern and has published in prestigious journals such as Journal of Clinical Oncology, Blood and JNCI Journal of the National Cancer Institute.

In The Last Decade

Susan M. Blaney

266 papers receiving 11.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study

2013 477 citations Yaël P. Mossé, Stephan D. Voss et al. profile →

Peers

Countries citing papers authored by Susan M. Blaney

Since Specialization

Citations

This map shows the geographic impact of Susan M. Blaney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan M. Blaney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan M. Blaney more than expected).

Fields of papers citing papers by Susan M. Blaney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan M. Blaney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan M. Blaney. The network helps show where Susan M. Blaney may publish in the future.

Co-authorship network of co-authors of Susan M. Blaney

This figure shows the co-authorship network connecting the top 25 collaborators of Susan M. Blaney. A scholar is included among the top collaborators of Susan M. Blaney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan M. Blaney. Susan M. Blaney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) 2021 ·Clinical Cancer Research ·Jennifer H. Foster, Stephan D. Voss, David Hall, Charles G. Minard, Frank M. Balis, Keith D. Wilner, Stacey L. Berg, Elizabeth Fox, Peter C. Adamson, Susan M. Blaney, Brenda J. Weigel, Yaël P. Mossé	61
2	Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children’s Oncology Group report 2021 ·Neuro-Oncology ·Jack Su, Lindsay Kilburn, David B. Mansur, Mark Krailo, Allen Buxton, (unknown), Amar Gajjar, Peter C. Adamson, Brenda J. Weigel, Elizabeth Fox, Susan M. Blaney, Maryam Fouladi	39
3	A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921) 2019 ·Clinical Cancer Research ·Yaël P. Mossé, Elizabeth Fox, David T. Teachey, Joel M. Reid, Stephanie L. Safgren, Hernán Carol, Richard B. Lock, Peter J. Houghton, Malcolm A. Smith, David Hall, Donald A. Barkauskas, Mark Krailo, Stephan D. Voss, Stacey L. Berg, Susan M. Blaney, Brenda J. Weigel	79
4	Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411) 2019 ·Pediatric Blood & Cancer ·Eric S. Schafer, Rachel E. Rau, Stacey L. Berg, Xiaowei Liu, Charles G. Minard, Alexander J.R. Bishop, July Carolina Romero, John Hicks, Marvin D. Nelson, Stephan D. Voss, Joel M. Reid, Elizabeth Fox, Brenda J. Weigel, Susan M. Blaney	52
5	A phase 1 study of eribulin mesylate (E7389), a novel microtubule‐targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314) 2018 ·Pediatric Blood & Cancer ·Eric S. Schafer, Rachel E. Rau, Stacey L. Berg, Xiaowei Liu, Charles G. Minard, David R. D’Adamo, Rachael Scott, Larisa Reyderman, (unknown), (unknown), Joel M. Reid, Elizabeth Fox, Brenda J. Weigel, Susan M. Blaney	14
6	Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study 2015 ·Child s Nervous System ·Lindsey M. Hoffman, Maryam Fouladi, James M. Olson, Vinay M. Daryani, Clinton F. Stewart, Cynthia Wetmore, Mehmet Koçak, Arzu Onar‐Thomas, Lars M. Wagner, Sridharan Gururangan, Roger J. Packer, Susan M. Blaney, Amar Gajjar, Larry E. Kun, James M. Boyett, Richard J. Gilbertson	41
7	Teledermatology as an Educational Tool for Teaching Dermatology to Residents and Medical Students 2015 ·Telemedicine Journal and e-Health ·Lindsay N. Boyers, (unknown), (unknown), Susan M. Blaney, (unknown), Robert P. Dellavalle, Cory A. Dunnick	55
8	A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report 2014 ·Clinical Cancer Research ·Maryam Fouladi, John P. Perentesis, Lars M. Wagner, Alexander A. Vinks, Joel M. Reid, Charlotte H. Ahern, George Thomas, Carol A. Mercer, Darcy A. Krueger, Peter J. Houghton, L. Austin Doyle, Helen Chen, Brenda J. Weigel, Susan M. Blaney	16
9	Phase I Pharmacokinetic and Pharmacodynamic Study of Pazopanib in Children With Soft Tissue Sarcoma and Other Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report 2013 ·Journal of Clinical Oncology ·Julia Glade Bender, Alice Lee, Joel M. Reid, Sylvain Baruchel, Timothy P. L. Roberts, Stephan D. Voss, Bing Wu, Charlotte H. Ahern, Ashish M. Ingle, Pamela Jo Harris, Brenda J. Weigel, Susan M. Blaney	125
10	Intravenous injection of oncolytic picornavirus SVV-001 prolongs animal survival in a panel of primary tumor–based orthotopic xenograft mouse models of pediatric glioma 2013 ·Neuro-Oncology ·Zhigang Liu, Xiumei Zhao, Hua Mao, Patricia Baxter, Yulun Huang, Litian Yu, Lalita Wadhwa, Jack M. Su, Adekunle M. Adesina, (unknown), Mary Y. Hurwitz, Neeraja Idamakanti, (unknown), Paul L. Hallenbeck, Richard L. Hurwitz, Ching C. Lau, Murali Chintagumpala, Susan M. Blaney, Xiao‐Nan Li	72
11	A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report 2012 ·Clinical Cancer Research ·Brigitte C. Widemann, AeRang Kim, Elizabeth Fox, Sylvain Baruchel, Peter C. Adamson, Ashish M. Ingle, Julia Glade Bender, Michael Burke, Brenda J. Weigel, Diana Stempak, Frank M. Balis, Susan M. Blaney	90
12	A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report 2012 ·Clinical Cancer Research ·Julia Glade Bender, Susan M. Blaney, Scott C. Borinstein, Joel M. Reid, Sylvain Baruchel, Charlotte H. Ahern, Ashish M. Ingle, Darrell J. Yamashiro, Alice P. Chen, Brenda J. Weigel, Peter C. Adamson, Julie R. Park	16
13	Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group 2011 ·Journal of Clinical Oncology ·Suman Malempati, Brenda J. Weigel, Ashish M. Ingle, Charlotte H. Ahern, Julie M. Carroll, Charles T. Roberts, Joel M. Reid, Stephen C. Schmechel, Stephan D. Voss, (unknown), Helen X. Chen, Mark Krailo, Peter C. Adamson, Susan M. Blaney	147
14	Phase I Trial of Lapatinib in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study 2010 ·Journal of Clinical Oncology ·Maryam Fouladi, Clinton F. Stewart, Susan M. Blaney, Arzu Onar‐Thomas, Paula Schaiquevich, Roger J. Packer, Amar Gajjar, Larry E. Kun, James M. Boyett, Richard J. Gilbertson	62
15	Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O 6-methylguanine-DNA methyltransferase activity 2009 ·Molecular Cancer Therapeutics ·Terzah M. Horton, (unknown), Debananda Pati, Linna Zhang, M. Eileen Dolan, Albert Ribes‐Zamora, Alison A. Bertuch, Susan M. Blaney, (unknown), Madhuri Hegde, Stacey L. Berg	67
16	Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children’s oncology group 2008 ·Cancer Chemotherapy and Pharmacology ·Patrick A. Thompson, Manish Gupta, Gary L. Rosner, Alexander Yu, Jeffrey S. Barrett, Lisa Bomgaars, Mark L. Bernstein, Susan M. Blaney, John Mondick	21
17	Expression Analysis of Juvenile Pilocytic Astrocytomas by Oligonucleotide Microarray Reveals Two Potential Subgroups 2005 ·Cancer Research ·Kwong‐Kwok Wong, (unknown), Yvonne T.M. Tsang, László Perlaky, Jack M. Su, (unknown), Dawna L. Armstrong, Meenakshi Bhattacharjee, Thomas Dauser, Susan M. Blaney, Murali Chintagumpala, Ching C. Lau	44
18	Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System: Report on Workshop 2002 ·Journal of Pediatric Hematology/Oncology ·Roger J. Packer, Jaclyn A. Biegel, Susan M. Blaney, Jonathan L. Finlay, J. Russell Geyer, Richard L. Heideman, Joanne M. Hilden, Anna J. Janss, Larry E. Kun, Gilbert Vézina, Lucy B. Rorke, Malcolm A. Smith	164
19	Phase I trial of 9-aminocamptothecin in children with refractory solid tumors: a Pediatric Oncology Group study. 1998 ·Journal of Clinical Oncology ·(unknown), Daniel T. Casto, Paul J. Thomas, Steven Weitman, C. Kretschmar, Holcombe E. Grier, C B Pratt, Ronald L. Dubowy, Mark Bernstein, Susan M. Blaney, Teresa J. Vietti	15
20	Clear Cell Sarcoma of the Kidney 1998 ·Journal of Pediatric Hematology/Oncology ·Suhag Parikh, Murali Chintagumpala, M J Hicks, (unknown), Susan M. Blaney, Paul K. Minifee, Shiao Y. Woo	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact